• +353-1-416-8900(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Fresenius SE & Co. KGaA Jul 11 Product Image

Fresenius SE & Co. KGaA Jul 11

  • Published: July 2011
  • Standard & Poors

FEATURED COMPANIES

  • FMC Finance VI S.A.
  • Fresenius Finance B.V.
  • Fresenius SE & Co. KGaA
  • MORE

Abstract
Leading positions in the global dialysis market and the European clinical nutrition and infusion therapy market. Presence in industries with positive underlying growth trends. Recurring revenues and cash flow stream from dialysis due to the terminal nature of kidney disease and lack of widely available substitutes. Geographically diverse asset base, which mitigates exposure to the economic cycles of individual countries. Aggressive financial policy owing to appetite for debt-financed acquisitions. Relatively high representation of dialysis-related revenues in the group's sales mix. Exposure to public funding and changes in reimbursement policies. The ratings on Germany-based health care group Fresenius SE & Co. KGaA (FSE) and its subsidiary Fresenius Medical Care AG & Co. KGaA (FME) reflect Standard & Poor's Ratings Services' view...

Companies mentioned in this report are:
- Fresenius SE & Co. KGaA
- Fresenius Medical Care AG & Co. KGaA
- Fresenius Finance B.V.
- Fresenius U.S. Finance I Inc.
- Fresenius U.S. Finance II Inc.
- FMC Finance VI S.A.
- Fresenius Medical Care US Finance, Inc

Action: Review

Standard READ MORE >

- Fresenius SE & Co. KGaA
- Fresenius Medical Care AG & Co. KGaA
- Fresenius Finance B.V.
- Fresenius U.S. Finance I Inc.
- Fresenius U.S. Finance II Inc.
- FMC Finance VI S.A.
- Fresenius Medical Care US Finance, Inc

Note: Product cover images may vary from those shown

RELATED PRODUCTS